USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market
06-Nov-2019
North America
Market Research
MECA-01-00-00-00
HC03223-GL-MT_23634
Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulation, but the importance of therapeutic and diagnostic products is rapidly increasing with more research substantiating the potential of microbiome-based therapy. Diagnostic applications of the microbiome include the diagnosis of infections and monitoring of microbial components related to non-communicable, chronic diseases.
The effect of next-generation sequencing (NGS) and the disruptive response to genomics has resulted in the development of novel, biomarker-based diagnostics and screening tests that only detect microbiome interactions or presence in humans. These are either direct-to-consumer products for more robust evaluations.
Because microbiome-based therapies constitute an entirely new therapeutic category, there is much uncertainty about the best paths to commercialization The United States is expected to have a faster adoption due to higher interest and awareness generated in this field by the Food and Drug Administration (FDA). One of the critical challenges in microbiome research is deciding whether a particular change in the microbiota is accountable for a specific condition, or if it is a side effect. The complexity of the microbiome and the fact that each person has a distinct one makes it extremely difficult to determine cause-effect relationships.
The global demand for more effective medicines and healthier nutrition will continue to drive the development of microbiomic products. Advancements in genomic sequencing and computer algorithms are expected to create both medicines and therapeutics based on individual microbiomes for better outcomes and healthier lives that will prevent or minimize diseases.
Research Highlights
This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive landscape, and key drivers and restraints, along with a revenue forecast for the human microbiome market.
Key Issues Addressed
- What is the market size and growth forecast for the human microbiome segments?
- Who are the key competitors in this market? How does the competitive landscape look like?
- What are the key growth opportunities for existing companies and new entrants in this market?
- What changes to the business model are required from companies to cater to changes in market conditions?
- How is the human microbiome market evolving? What are the key partnerships and collaborations in this industry?
- What are the strategic imperatives for human microbiome industry participants?
Purpose of this Experiential Study
5-Step Process to Transformational Growth
Market Scope and Segmentation
Key Questions this Study will Answer
Market Snapshot
Market Engineering Measurements—Human Microbiome Market
Key Findings
Frost & Sullivan’s Big Market Prospects
Major Growth Opportunities
Microbiome Ecosystem—Industry Convergence Map
Strategic Imperatives for Growth
Market Definition
Key Types of Microbiome Therapeutics
Understanding Human Microbiome—Major Initiatives
Understanding Human Microbiome—Major Initiatives (continued)
Drivers and Restraints
Impact Mapping of Drivers and Restraints
Key Challenges in the Human Microbiome Market
Areas That Will Highly Impact Microbiome Adoption
Regulatory Scenario Assessment—OTC Segment
Regulatory Scenario Assessment—OTC Segment (continued)
Regulatory Scenario Assessment—Microbiome-based Drugs
Regulatory Scenario Assessment—Microbiome-based Drugs (continued)
Regulatory Scenario Assessment—Microbiome-based Drugs (continued)
Market Engineering Measurements—Human Microbiome Market
Forecast Assumptions
Revenue Forecast
Forecast Discussions
Revenue Forecast by Segment
Microbiome-based Drugs—Pipeline Analysis
Microbiome-based Drugs—Pipeline Analysis (continued)
Microbiome-based Drugs—Pipeline Analysis (continued)
Key Microbiome-based Drugs to Watch
Vendor Ecosystem
Key Companies to Watch—Enterome Bioscience
Key Companies to Watch—Chr. Hansen
Key Companies to Watch—Seres Therapeutics
Key Companies to Watch—Viome
Other Companies to Watch—Microbiome Therapeutics
Other Companies to Watch—Microbiome Diagnostics
Analysis of Big Pharma Spend on Human Microbiome Market
Analysis of Big Pharma Spend on Human Microbiome Market (continued)
Key Licensing Deals Analysis
Key Licensing Deals Analysis (continued)
Key Licensing Deals Analysis (continued)
Key Companies by Therapeutic Area of Focus and Stage of Microbiome Therapeutic Candidate
Human Microbiome Market—Macro to Micro Visioning
Key Future Trends in the Human Microbiome Market
Levers for Growth
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies (continued)
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies (continued)
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 3—Wellness and Data Monetization Through DTCMT
Growth Opportunity 3—Wellness and Data Monetization Through DTCMT (continued)
Growth Opportunity 4—Microbiome (OTC and Therapeutic) Contract Manufacturing
Growth Opportunity 4—Microbiome (OTC and Therapeutic) Contract Manufacturing (continued)
Growth Opportunity Matrix
Focus Geographies for Human Microbiome Companies
Key Therapeutic Areas to Look Out for in Future
Strategic Imperatives for Human Microbiome Companies
3 Big Predictions
Legal Disclaimer
Research Till Date Has Identified Broadly 9 Therapy Areas Which Includes Multiple Chronic Diseases
List of Exhibits
List of Exhibits (continued)
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Highlights
This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive landscape, and key drivers and restraints, along with a revenue forecast for the human microbiome market.
Key Issues Addressed
- What is the market size and growth forecast for the human microbiome segments?
- Who are the key competitors in this market? How does the competitive landscape look like?
- What are the key growth opportunities for existing companies and new entrants in this market?
- What changes to the business model are required from companies to cater to changes in market conditions?
- How is the human microbiome market evolving? What are the key partnerships and collaborations in this industry?
- What are the strategic imperatives for human microbiome industry participants?
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Saravanan Thangaraj |
| Industries | Healthcare |
| WIP Number | MECA-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9562-B1,9571-B1,9573-B1,99C1-B1,99C6-B1,9568-B1,9611-B1,9627-B1 |
Growth Opportunities in Human Microbiome Market, Forecast to 2023
$4,950.00
Special Price $3,712.50 save 25 %